132 related articles for article (PubMed ID: 29126304)
1. SDHC Promoter Methylation, a Novel Pathogenic Mechanism in Parasympathetic Paragangliomas.
Bernardo-Castiñeira C; Valdés N; Sierra MI; Sáenz-de-Santa-María I; Bayón GF; Perez RF; Fernández AF; Fraga MF; Astudillo A; Menéndez R; Fernández B; Del Olmo M; Suarez C; Chiara MD
J Clin Endocrinol Metab; 2018 Jan; 103(1):295-305. PubMed ID: 29126304
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
[TBL] [Abstract][Full Text] [Related]
3. Identification of a signaling axis HIF-1α/microRNA-210/ISCU independent of SDH mutation that defines a subgroup of head and neck paragangliomas.
Merlo A; de Quiros SB; Secades P; Zambrano I; Balbín M; Astudillo A; Scola B; Arístegui M; Suarez C; Chiara MD
J Clin Endocrinol Metab; 2012 Nov; 97(11):E2194-200. PubMed ID: 22977270
[TBL] [Abstract][Full Text] [Related]
4. Role of VHL, HIF1A and SDH on the expression of miR-210: Implications for tumoral pseudo-hypoxic fate.
Merlo A; Bernardo-Castiñeira C; Sáenz-de-Santa-María I; Pitiot AS; Balbín M; Astudillo A; Valdés N; Scola B; Del Toro R; Méndez-Ferrer S; Piruat JI; Suarez C; Chiara MD
Oncotarget; 2017 Jan; 8(4):6700-6717. PubMed ID: 28036268
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance and peculiarities of succinate dehydrogenase B and hypoxia inducible factor 1α expression in parasympathetic versus sympathetic paragangliomas.
Bernardo-Castiñeira C; Sáenz-de-Santa-María I; Valdés N; Astudillo A; Balbín M; Pitiot AS; Jiménez-Fonseca P; Scola B; Tena I; Molina-Garrido MJ; Sevilla MA; Beristein E; Forga L; Villabona C; Oriola J; Halperin I; Suarez C; Chiara MD
Head Neck; 2019 Jan; 41(1):79-91. PubMed ID: 30549360
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic Mutation of the Succinate Dehydrogenase C Promoter in a Patient With Two Paragangliomas.
Richter S; Klink B; Nacke B; de Cubas AA; Mangelis A; Rapizzi E; Meinhardt M; Skondra C; Mannelli M; Robledo M; Menschikowski M; Eisenhofer G
J Clin Endocrinol Metab; 2016 Feb; 101(2):359-63. PubMed ID: 26652933
[TBL] [Abstract][Full Text] [Related]
7. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J
J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498
[TBL] [Abstract][Full Text] [Related]
8. The mTORC1 Complex Is Significantly Overactivated in SDHX-Mutated Paragangliomas.
Oudijk L; Papathomas T; de Krijger R; Korpershoek E; Gimenez-Roqueplo AP; Favier J; Canu L; Mannelli M; Rapa I; Currás-Freixes M; Robledo M; Smid M; Papotti M; Volante M
Neuroendocrinology; 2017; 105(4):384-393. PubMed ID: 28122379
[TBL] [Abstract][Full Text] [Related]
9. Potential Pitfalls of SDH Immunohistochemical Detection in Paragangliomas and Phaeochromocytomas Harbouring Germline
Santi R; Rapizzi E; Canu L; Ercolino T; Baroni G; Fucci R; Costa G; Mannelli M; Nesi G
Anticancer Res; 2017 Feb; 37(2):805-812. PubMed ID: 28179334
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic variability and risk of malignancy in SDHC-linked paragangliomas: lessons from three unrelated cases with an identical germline mutation (p.Arg133*).
Bickmann JK; Sollfrank S; Schad A; Musholt TJ; Springer E; Miederer M; Bartsch O; Papaspyrou K; Koutsimpelas D; Mann WJ; Weber MM; Lackner KJ; Rossmann H; Fottner C
J Clin Endocrinol Metab; 2014 Mar; 99(3):E489-96. PubMed ID: 24423348
[TBL] [Abstract][Full Text] [Related]
11. Identification of somatic VHL gene mutations in sporadic head and neck paragangliomas in association with activation of the HIF-1α/miR-210 signaling pathway.
Merlo A; de Quirós SB; de Santa-María IS; Pitiot AS; Balbín M; Astudillo A; Scola B; Arístegui M; Quer M; Suarez C; Chiara MD
J Clin Endocrinol Metab; 2013 Oct; 98(10):E1661-6. PubMed ID: 23902947
[TBL] [Abstract][Full Text] [Related]
12. High frequency of germline succinate dehydrogenase mutations in sporadic cervical paragangliomas in northern Spain: mitochondrial succinate dehydrogenase structure-function relationships and clinical-pathological correlations.
Lima J; Feijão T; Ferreira da Silva A; Pereira-Castro I; Fernandez-Ballester G; Máximo V; Herrero A; Serrano L; Sobrinho-Simões M; Garcia-Rostan G
J Clin Endocrinol Metab; 2007 Dec; 92(12):4853-64. PubMed ID: 17848412
[TBL] [Abstract][Full Text] [Related]
13. Biallelic inactivation of the SDHC gene in renal carcinoma associated with paraganglioma syndrome type 3.
Malinoc A; Sullivan M; Wiech T; Schmid KW; Jilg C; Straeter J; Deger S; Hoffmann MM; Bosse A; Rasp G; Eng C; Neumann HP
Endocr Relat Cancer; 2012 Jun; 19(3):283-90. PubMed ID: 22351710
[TBL] [Abstract][Full Text] [Related]
14. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene.
Schiavi F; Boedeker CC; Bausch B; Peçzkowska M; Gomez CF; Strassburg T; Pawlu C; Buchta M; Salzmann M; Hoffmann MM; Berlis A; Brink I; Cybulla M; Muresan M; Walter MA; Forrer F; Välimäki M; Kawecki A; Szutkowski Z; Schipper J; Walz MK; Pigny P; Bauters C; Willet-Brozick JE; Baysal BE; Januszewicz A; Eng C; Opocher G; Neumann HP;
JAMA; 2005 Oct; 294(16):2057-63. PubMed ID: 16249420
[TBL] [Abstract][Full Text] [Related]
15. Recurrent epimutation of SDHC in gastrointestinal stromal tumors.
Killian JK; Miettinen M; Walker RL; Wang Y; Zhu YJ; Waterfall JJ; Noyes N; Retnakumar P; Yang Z; Smith WI; Killian MS; Lau CC; Pineda M; Walling J; Stevenson H; Smith C; Wang Z; Lasota J; Kim SY; Boikos SA; Helman LJ; Meltzer PS
Sci Transl Med; 2014 Dec; 6(268):268ra177. PubMed ID: 25540324
[TBL] [Abstract][Full Text] [Related]
16. The VHL gene is epigenetically inactivated in pheochromocytomas and abdominal paragangliomas.
Andreasson A; Kiss NB; Caramuta S; Sulaiman L; Svahn F; Bäckdahl M; Höög A; Juhlin CC; Larsson C
Epigenetics; 2013 Dec; 8(12):1347-54. PubMed ID: 24149047
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and spectrum of SDHx mutations in pheochromocytoma and paraganglioma in patients from Belgium: an update.
Persu A; Lannoy N; Maiter D; Mendola A; Montigny P; Oriot P; Vinck W; Garin P; Hamoir M; Vikkula M
Horm Metab Res; 2012 May; 44(5):349-53. PubMed ID: 22566194
[TBL] [Abstract][Full Text] [Related]
18. AN AGGRESSIVE TEMPORAL BONE SDHC PARAGANGLIOMA ASSOCIATED WITH INCREASED HIF-2α SIGNALING.
Isaacson B; Bullova P; Frone M; Click A; Hamplova B; Rabaglia J; Woodruff S; Nwariaku F; Kathuria A; Pacak K; Ghayee HK
Endocr Pract; 2016 Feb; 22(2):190-5. PubMed ID: 26492543
[TBL] [Abstract][Full Text] [Related]
19. SDHB, SDHC, and SDHD mutation screen in sporadic and familial head and neck paragangliomas.
Mhatre AN; Li Y; Feng L; Gasperin A; Lalwani AK
Clin Genet; 2004 Nov; 66(5):461-6. PubMed ID: 15479192
[TBL] [Abstract][Full Text] [Related]
20. A SDHC Founder Mutation Causes Paragangliomas (PGLs) in the French Canadians: New Insights on the SDHC-Related PGL.
Bourdeau I; Grunenwald S; Burnichon N; Khalifa E; Dumas N; Binet MC; Nolet S; Gimenez-Roqueplo AP
J Clin Endocrinol Metab; 2016 Dec; 101(12):4710-4718. PubMed ID: 27700540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
